Overview

Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion Dependence

Status:
Recruiting
Trial end date:
2024-10-15
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the efficacy and safety of eltrombopag monotherapy in Japanese adult patients with platelet transfusion-dependent lower-risk Myelodysplastic syndromes (LR-MDS).
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals